CoChat
Sign Up
Cited by 540Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

Open access
Frattini, M, Saletti, P, Romagnani, E, Martin, V, Molinari, F, Ghisletta, M, Camponovo, A, Etienne, L L, Cavalli, F, Mazzucchelli, L·2007·British Journal of Cancer
DOI 10.1038/sj.bjc.6604009PMC PMC2360431
Open this paper in CoChat — free accountOpen PDF

Abstract

To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway, may affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated mCRC patients were evaluated for drug response and investigated for EGFR protein expression and gene status, K-Ras mutational status and PTEN protein expression. Ten patients achieved a partial response (PR) to cetuximab-based therapy. All 27 patients showed EGFR protein overexpression. Epidermal growth factor receptor gene amplification was observed in eight out of 27 (30%) and chromosome 7 marked polysomy in 16 (59%) patients. Partial response was observed in six out of eight patients with EGFR gene amplification, four out of 16 with marked polysomy and none out of three with eusomy (P<0.05). The K-Ras wild-type sequence was observed in 17 patients, and nine of them experienced a PR. Conversely, K-Ras was mutated in 10 cases, of which one patient experienced a PR (P<0.05). The PTEN protein was normally expressed in 16 patients, and 10 of them achieved a PR. In contrast, no benefit was documented in 11 patients with loss of PTEN activity (P<0.001). Patients with EGFR gene amplification or chromosome 7 marked polysomy respond to cetuximab. In addition to K-Ras mutations, we demonstrate for the first time that the loss of PTEN protein expression is associated with nonresponsiveness to cetuximab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604009

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Epidermal growth factor receptor gene status evaluated by FISH in metastatic colorectal cancers. (A) Patient showing eusomy of chromosome 7. (B) Patient with marked polysomy on chromosome 7. (C) Patient with EGFR gene amplification in at least 10% of tumoral cells.
Figure 1 Epidermal growth factor receptor gene status evaluated by FISH in metastatic colorectal cancers. (A) Patient showing eusomy of chromosome 7. (B) Patient with marked polysomy on chromosome 7. (C) Patient with EGFR gene amplification in at least 10% of tumoral cells.CC BY · PubMed Central
Figure 2 PTEN protein expression by immunohistochemistry in metastatic colorectal cancers. (A) Patient showing normal PTEN expression. (B) Patient with absent PTEN expression.
Figure 2 PTEN protein expression by immunohistochemistry in metastatic colorectal cancers. (A) Patient showing normal PTEN expression. (B) Patient with absent PTEN expression.CC BY · PubMed Central
Figure 3 Algorithm in predicting response to cetuximab according to the EGFR and K-Ras status, and PTEN protein expression.
Figure 3 Algorithm in predicting response to cetuximab according to the EGFR and K-Ras status, and PTEN protein expression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 4

  1. Jennis A, Polikoff J, Mitchell E, Badarinath S, Graham C, Chen T, Gustafson T, Langer C (2005) Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomised phase III trial. J Clin Oncol 23(16S): 3574
  2. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E, Ramos L, Saltz LB (2002) Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 21: 536
  3. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 20: 7
  4. Van Laethem JL, Raoul JL, Mitry E, Brezault C, Husseini F, Cals L, Vedovato JC, Mueser MM, Rougier P (2003) Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 22: 1058

Cited by

Sorted by citations

See all 540

Related

Metadata

Authors
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L.
Affiliations
  • Istituto Cantonale di Patologia (CH)
  • Ospedale San Giovanni Bellinzona (CH)
Corresponding author
Frattini, M
ORCID
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2007-10
Volume
97
Issue
8
Pages
1139-1145
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
DOI
10.1038/sj.bjc.6604009
PMC
PMC2360431
OpenAlex
W2100589633
Cited by
540
References
31
Citations by year
2026: 3 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 14 · 2018: 9 · 2017: 15 · 2016: 20 · 2015: 30 · 2014: 38 · 2013: 38 · 2012: 63
FWCI
33.57
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Oncosuisse
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
PTEN loss, cetuximab, metastatic colorectal cancer, EGFR overexpression, EGFR amplification, KRAS mutation, chromosome 7 polysomy, drug response prediction, predictive biomarkers
MeSH terms
Cetuximab, Adult, Aged, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Chromosomes, Human, Pair 7, Female, Gene Amplification, Humans, Immunohistochemistry, Male, Middle Aged, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Gene Expression, Proto-Oncogene Proteins p21(ras), In Situ Hybridization, Fluorescence, ras Proteins, Drug Resistance, Neoplasm, PTEN Phosphohydrolase, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review